Cel-Sci Corporation (CVM) vs IGC Pharma, Inc. (IGC)

Cel-Sci Corporation and IGC Pharma, Inc. are both Biotechnology companies. Cel-Sci Corporation and IGC Pharma, Inc. are of similar size ($30.3M and $29.1M). Cel-Sci Corporation grew revenue faster over the last twelve months: 20.8% against −13.4%. Cel-Sci Corporation has the higher net margin (0.00% vs −795.5%) and the lower return on invested capital (−169.6% vs −91.5%). Across the 18 metrics below, IGC Pharma, Inc. leads on 10 and Cel-Sci Corporation on 8.

Valuation

Metric CVM IGC Biotechnology median
P/E n/m n/m 7.88
P/S 36.22 25.52 11.47
P/B 1.85 4.58 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 34.83 26.18 10.73
Earnings yield (68.40%) (32.14%) (28.84%)
Free cash flow yield (83.02%) (20.24%) (23.03%)

Profitability

Metric CVM IGC Biotechnology median
Gross margin 0.00% 32.33% 65.16%
Operating margin 0.00% (912.44%) 0.00%
Net margin 0.00% (795.46%) 0.00%
Free cash flow margin 0.00% (516.53%) 0.00%
Return on equity (252.53%) (143.46%) (57.72%)
Return on assets (108.91%) (100.44%) (49.22%)
Return on invested capital (169.59%) (91.53%) 0.00%

Growth

Metric CVM IGC Biotechnology median
Revenue growth (TTM) 20.75% (13.38%) 5.64%
EPS growth (last fiscal year) 59.06% 57.85% —
Revenue growth, 5-year CAGR 16.18% (20.77%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CVM IGC Biotechnology median
Debt to equity 0.35 0.18 0.00
Current ratio 1.48 0.39 4.73
Net debt to EBITDA 0.25 0.04 0.96

Dividend

Metric CVM IGC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CVM IGC Biotechnology median
Market cap 30.25m 29.11m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack